Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.

Employees

1,041

Sector

Pharmaceuticals

Calendar

02-11 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-12-05	34.98 $	+1.10%	171,718
25-12-04	34.60 $	+1.70%	982,834
25-12-03	34.02 $	+0.06%	1,695,644
25-12-02	34.00 $	+1.19%	1,180,621
25-12-01	33.60 $	0.00%	1,697,267

Delayed Quote Nasdaq, December 05, 2025 at 10:43 am

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

34.60USD

Average target price

37.86USD

Spread / Average Target

+9.41%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 10:58:53 2025-12-05 EST			5-day change	1st Jan Change
34.88 ^USD	+0.82%		+4.09%	+181.38%

11-14	Camurus Competitor Exits Sweden - Di	FW
11-03	Indivior Presents New Real-World Evidence At AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	CI

Capitalization	4.32B 3.7B 3.46B 3.24B 6.02B 388B 6.53B 40.64B 15.68B 183B 16.21B 15.87B 669B	P/E ratio 2025 *	19.7x	P/E ratio 2026 *	14.3x
Enterprise value	4.22B 3.62B 3.39B 3.16B 5.89B 379B 6.38B 39.74B 15.34B 179B 15.86B 15.52B 654B	EV / Sales 2025 *	3.55x	EV / Sales 2026 *	3.45x
Free-Float	96.11%	Yield 2025 *	-	Yield 2026 *	-

11-14	Camurus Competitor Exits Sweden - Di	FW
11-03	Indivior Presents New Real-World Evidence At AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	CI
10-30	Sector Update: Health Care Stocks Rise Late Afternoon	MT
11-27	Indivior PLC, Q3 2025 Earnings Call, Oct 30, 2025
10-30	Top Midday Gainers	MT
10-30	Indivior PLC Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
10-30	Indivior Q3 Adjusted Earnings, Revenue Rise; 2025 Revenue Outlook Raised - Shares Up Pre-Bell	MT
10-30	Indivior PLC Raises Earnings Guidance for the Year 2025	CI
10-30	Earnings Flash (INDV) Indivior PLC Reports Q3 Revenue $314.0M, vs. FactSet Est of $261.9M	MT
10-30	Earnings Flash (INDV) Indivior PLC Posts Q3 Adjusted EPS $0.72 per Share, vs. FactSet Est of $0.41	MT
10-15	Indivior Says Rapid Sublocade Induction Improves Retention in Opioid Use Disorder Trial	MT
10-15	Indivior PLC Publishes Completes Results from a Multicenter, Open-Label Clinical Trial Published in JAMA Network Open	CI
10-01	UK's Indivior to re-domicile to US after listing move	RE

10-15	Indivior PLC Publishes Completes Results from a Multicenter, Open-Label Clinical Trial Published in JAMA Network Open	CI
08-06	HC Wainwright Initiates Indivior at Buy With $28 Price Target	MT
07-28	Jefferies Initiates Coverage on Indivior With Buy Rating, $20 Price Target	MT

Indivior PLC Stock

Equities

INDV

GB00BN4HT335

Pharmaceuticals

Valuation: Indivior PLC

Chart: Indivior PLC

Latest news: Indivior PLC

Last Transcript: Indivior PLC

Analysts' recommendations: Indivior PLC

Press Releases: Indivior PLC

News in other languages: Indivior PLC

Quotes and Performance

Course Extremes

Managers and Directors: Indivior PLC

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

11-20	Indivior Concludes Legacy U.S. Department of Justice Matter	PR
11-19	Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference	PR
11-18	Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	AQ
11-03	Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	PR
10-30	Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance	PR

12-04	Addex mit leicht tieferen Cash-Beständen per Ende September
10-29	Addex erhöht Aktienkapital
09-30	Addex sieht sich nach zweitem Quartal auf Kurs
07-28	Avis d'analystes du jour : Rémy Cointreau revient en grâce, Puma et Swatch se font corriger
07-28	L'UE accepte une pilule de 15%

1 day	+0.62%
1 week	+4.09%
Current month	+4.09%
1 month	+9.13%
3 months	+40.01%
6 months	+157.36%
Current year	+181.38%

1 week	33.45	35.14
1 month	29.39	35.14
Current year	7.62	35.14
1 year	7.62	35.14
3 years	7.33	35.14
5 years	6.25	35.14
10 years	1.75	35.14

Manager	Title	Age	Since
Joseph Ciaffoni CEO	Chief Executive Officer	54	-
Ryan Preblick DFI	Director of Finance/CFO	49	2020-06-28
Kevin L. Espinoza CMP	Compliance Officer	-	2025-09-30

Director	Title	Age	Since
Juliet Thompson BRD	Director/Board Member	58	2021-03-23
Mark Stejbach BRD	Director/Board Member	62	2021-03-23
Barbara Ryan BRD	Director/Board Member	65	2022-05-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
INDIVIOR PLC	+0.82%	+4.09%	+210.89%	+66.47%	4.32B
MERCK KGAA	+1.34%	+4.40%	-13.47%	-31.47%	60.54B
KYOWA KIRIN CO., LTD.	-1.01%	-3.23%	+4.01%	-18.49%	8.69B
HALOZYME THERAPEUTICS, INC.	+1.02%	-10.92%	+32.34%	+13.70%	7.4B
SK BIOPHARMACEUTICALS CO., LTD.	-1.69%	-3.67%	+30.22%	+84.83%	7.25B
YUHAN CORPORATION	-0.93%	-2.41%	-0.51%	+121.82%	6B
BETTA PHARMACEUTICALS CO., LTD.	+0.61%	-3.33%	-14.05%	-4.85%	2.82B
SUPERNUS PHARMACEUTICALS, INC.	+0.23%	-0.79%	+22.28%	+27.01%	2.59B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.67%	+2.72%	+22.49%	+71.21%	2.56B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+0.19%	+0.19%	-14.42%	+7.72%	1.96B
Average	-0.04%	-2.08%	+27.98%	+33.80%	10.41B
Weighted average by Cap.	+0.58%	+0.26%	+6.08%	-0.75%

	2025 *	2026 *
Net sales	1.19B 1.02B 954M 891M 1.66B 107B 1.8B 11.19B 4.32B 50.49B 4.47B 4.37B 184B	1.13B 972M 909M 849M 1.58B 102B 1.71B 10.66B 4.11B 48.11B 4.25B 4.16B 175B
Net income	225M 193M 180M 168M 313M 20.17B 339M 2.11B 815M 9.53B 843M 825M 34.75B	312M 268M 250M 234M 435M 28.03B 471M 2.94B 1.13B 13.24B 1.17B 1.15B 48.29B
Net Debt	-95.36M -81.77M -76.47M -71.42M -133M -8.57B -144M -897M -346M -4.05B -358M -350M -14.76B	-410M -351M -328M -307M -571M -36.79B -619M -3.85B -1.49B -17.38B -1.54B -1.5B -63.38B